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In patients with advanced human
immunodeficiency virus (HIV) infection, aphthous ul-
ceration of the mouth and oropharynx can become
extensive and debilitating. Preliminary reports sug-





We performed a double-blind, random-
ized, placebo-controlled study of thalidomide as
therapy for oral aphthous ulcers in HIV-infected pa-
tients. The patients received a four-week course of
either 200 mg of thalidomide or placebo orally once
per day. They were evaluated weekly for the condi-
tion of the ulcers, their quality of life, and evidence


















Sixteen of 29 patients in the thalidomide
group (55 percent) had complete healing of their
aphthous ulcers after four weeks, as compared with
only 2 of 28 patients in the placebo group (7 per-
cent; odds ratio, 15; 95 percent confidence interval





0.001). Pain diminished and the
ability to eat improved with thalidomide treatment.
The adverse effects noted with thalidomide included
somnolence and rash (7 patients each), and 6 of the
29 patients discontinued treatment because of toxic-
ity. Thalidomide treatment increased HIV RNA levels




 copies per milliliter; in-





mide treatment there were unexpected increases in













Thalidomide is an effective treat-
ment for aphthous ulceration of the mouth and
oropharynx in patients with HIV infection. (N Engl J
Med 1997;336:1487-93.)
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PHTHOUS ulceration of the mouth,
though painful and annoying, is usually a





 In patients with human
immunodeficiency virus (HIV) infection, however,





 Extremely painful, en-
larging necrotic lesions can develop, resembling the
large aphthous ulcers often seen in patients with Beh-
çet’s syndrome. The hypopharynx and esophagus may
A
 
be involved. Aphthous ulcers can interfere with eat-
ing and lead to malnutrition and wasting. Even when
the ulcers regress, they tend to recur.
Available treatments for aphthous ulcers in HIV-
infected patients are unsatisfactory. Some success
has been reported with topical, intralesional, and
systemic corticosteroids, but the responses are not





studies of this treatment have been performed, and
long-term treatment with systemic corticosteroids
may cause further immunosuppression in already im-
munocompromised patients.








-phthalimidoglutarimide, is effective for the se-





 As part of AIDS Clinical Trials
Group (ACTG) protocol 251 of the National Insti-
tute of Allergy and Infectious Diseases (NIAID), we
performed a multicenter, double-blind, randomized,
placebo-controlled study of the usefulness of thalid-
omide in treating oral aphthous ulcers in HIV-
infected persons. In addition, since thalidomide has













 a substance known to















We enrolled patients in the study if they met the following cri-
teria: an age of at least 13 years; documented HIV infection; oral
aphthous ulceration of at least two weeks’ duration, as confirmed
by a biopsy that revealed no infectious, neoplastic, or other spe-
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cific diagnosis; a surface diameter of at least 5 mm for the largest
ulcer; a negative culture of the ulcer for herpes simplex virus; a
hemoglobin concentration greater than 8 g per deciliter; an ab-
solute neutrophil count greater than 500 per cubic millimeter; a
platelet count greater than 50,000 per cubic millimeter; a serum
bilirubin concentration no higher than 2.5 times the upper limit
of normal; serum concentrations of aspartate aminotransferase
and alkaline phosphatase less than 5 times the upper limit of nor-






Patients were excluded from the study if they had bilateral pe-
ripheral neuropathy more severe than grade 1 or a history of such
neuropathy, a known allergy to thalidomide, or prior treatment
of aphthous ulcers with thalidomide; if they were pregnant or lac-
tating; if they were receiving short-term therapy for opportunistic
infections; if they were receiving radiation to the head or neck; if
they had been treated with systemic or oral topical corticosteroids
within one week before the first set of blood tests; if they were
treated with other putative immunomodulators within the two
weeks before entry into the study and during the study; if they
were undergoing systemic cancer chemotherapy; if they were
treated with antiinfective mouthwashes; and if they were receiving
zalcitabine, pentoxifylline, methotrexate, trimetrexate, or antine-
oplastic alkylating agents. If a patient had received any of the lat-
ter group of medications within eight weeks before entering the
study, the patient’s aphthous ulcers had to have persisted for at
least four weeks after the medication was discontinued. Anti-HIV
therapy was held constant beginning four weeks before study
entry. Antimicrobial prophylaxis against opportunistic infections
was permitted.
Patients were recruited at 19 sites in the United States. The
study was approved by the institutional review board of each
medical center. The patients gave written informed consent to par-
ticipate. Precautions were taken to prevent and detect pregnancy,




The patients were randomly assigned to receive a four-week
course of either two 100-mg capsules of thalidomide or two pla-
cebo capsules orally once a day at bedtime (the study medications
were kindly provided by Andrulis Pharmaceuticals, Beltsville,
Md.). Patients whose aphthous ulcers had not completely healed
by the end of the four weeks were offered the option of taking
two 100-mg capsules of open-label thalidomide daily for the next
four weeks. If the healing was still not complete after that period,
200 mg of thalidomide could be given twice a day for an addi-
tional four weeks as tolerated.
As specified in the study protocol, in the event of sedation or
other adverse effects, depending on their nature and grade (as de-
fined according to the NIAID criteria), the dose was reduced, the
study medication was permanently discontinued, or the medica-
tion was withheld until the adverse effect had resolved, at which




One end point of the study was the complete absence of oral
aphthous ulcers after four weeks of study treatment (a complete
response). If a patient discontinued the study treatment before
the end of four weeks because of toxicity, the response was not
considered complete unless there was complete healing at the
time of the discontinuation and the complete healing lasted until
the four-week visit. A partial response at week 4 was defined as a
decrease of 50 percent or more in the combined surface area of
the three largest ulcers, as compared with the area of the three
largest ulcers at base line, with no formation of new ulcers. (The
surface area was defined as the product of the ulcer’s largest sur-
face diameter and its largest perpendicular surface diameter.) A
lack of response was defined as a decrease of less than 50 percent
or the occurrence of a new ulcer.
An additional, independent end point was the change in the
HIV load, as measured by the plasma HIV RNA level, from base
line to week 4.
 
Evaluation of Patients and Follow-up
 
After the screening and base-line evaluations, the patients were
seen weekly by site investigators unaware of the patients’ treat-





HIV load, in order to assess the healing of oral ulcers and toxic
effects of the study medication. At base line and at each weekly
visit, a quality-of-life questionnaire was administered to assess pain
and eating ability; neuropathy was assessed; and there were labo-
ratory evaluations of blood cells, serum chemistries, serum thalid-
omide levels, and hepatic and renal function. Plasma samples for








 receptor type II, and
HIV RNA were obtained at base line and every two weeks. CD4
and CD8 lymphocyte counts were performed at base line and




 subunit of human chorionic
gonadotropin in serum was performed weekly on women with
childbearing potential and was repeated four weeks after the dis-




The quality-of-life questionnaire contained 15 items that meas-
ured general health, pain, and eating ability during the study.





sessed general perceptions of health and pain; they were supple-
mented by an item assessing the patient’s pain while eating. Two
scales with six items each assessed discomfort while eating and the
actual consumption of food (the latter scale was modified from




). The responses to these questions
were scored on scales ranging from 1 to 5 or 1 to 6, with higher
numbers indicating poorer health or more severe symptoms.
 
TNF Measurements and Virologic Assays
 









II, and HIV-1 RNA were performed at the end of the study. Plas-









fied-sensitivity immunoassay kits (Medgenix, Incstar, Stillwater,
Minn.), and levels of soluble TNF receptor II were measured with
HyCult enzyme-linked immunosorbent assay kits (Caltag, San
Francisco). The assays were performed in an ACTG Advanced
Technology Laboratory (University of California at Los Angeles).
The samples from each patient were batch-tested in a single run.
For quality control, 15 percent of the samples were retested in a
subsequent run to confirm the results of the first run. 
HIV-1 RNA levels in plasma collected in acid–citrate–dextrose
were determined in a single ACTG-certified laboratory by the





 with the Viral Quality Assurance Program standards of the
National Institutes of Health. Each patient’s samples were batch-
tested in a single run with detection on the same microtiter plate
to minimize variability.
 
Statistical Analysis and Interim Data Monitoring
 
The study was designed to have 80 percent power and type I
error rates of 0.05 for the independent end points of complete
ulcer resolution and change in HIV load at week 4. The study
was not designed for the formal testing of hypotheses about other
end points; we present those findings for exploratory purposes
only, without adjusting the type I error rates for multiple testing.
All the analyses were performed on an intention-to-treat basis, ex-
cept that three patients who did not begin the study treatment
were excluded.
For continuous and ordinal variables, appropriate two-tailed





 Two-by-two classifications of ulcer-related and other di-





strength of the association between the variables used in the anal-
ysis was estimated with Spearman’s rank-correlation coefficient.
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The distributions of the time to ulcer healing were estimated by




The study design included a group sequential interim analysis
of the ulcer-healing end point for the first 45 of 82 intended pa-





sults of the interim analysis were presented to an ad hoc interim-
review committee. On the basis of these findings, enrollment in
the placebo group was closed, by which time 12 more patients
had completed four weeks of randomized study treatment. Re-
sults for all 57 patients (which were virtually identical to the re-






Between February 1994 and October 1995, 60
patients were enrolled. Three patients were excluded
from the analysis because they never received treat-
ment according to the study protocol. The ulcers of
two of the three patients healed between the time
of the screening visit and the time the study treat-
ment was scheduled to begin; the third patient was
found after randomization to be ineligible for the
study. Of the 57 patients included in the analysis, 28
were randomly assigned to receive placebo and 29
were assigned to receive thalidomide. The patients in
the two groups had similar base-line characteristics
(Table 1). Almost all had substantial pain that im-
paired their eating and overall health. Only one pa-





Among the 29 patients in the thalidomide group,
16 (55 percent) had responded to therapy complete-
ly at week 4, as compared with 2 of the 28 patients
in the placebo group (7 percent; odds ratio, 15;
95 percent confidence interval after adjustment for





0.001) (Fig. 1). For the patients in the thalido-
mide group who had complete responses, the medi-
an time to complete ulcer healing was 3.5 weeks (95
percent confidence interval, 2 to 4). Once the pa-
tients randomly assigned to placebo were offered
open-label thalidomide after week 4, their rate
of complete response was similar to the initial rate
of complete response in the thalidomide group
(Fig. 2).
If one combines complete and partial responses,
the results show a similar pattern. Of the 29 patients
in the thalidomide group, 26 (90 percent) had com-
plete or partial responses at the end of week 4, as
compared with only 7 of 28 patients in the placebo
group (25 percent; odds ratio, 24; 95 percent con-





Seven patients received the higher dose of thalido-
mide (200 mg twice a day) because their ulcers were
still present. Five of these patients had complete
healing.
The quality-of-life data showed that the patients
in the thalidomide group succeeded much more than
those in the placebo group in attaining a relatively









0.03] except general health). The improve-
ment was greatest with regard to the patients’ dis-





The patients in the thalidomide group gained a
median of 1.8 kg (4 lb) during the first four weeks
of the study, whereas there was no weight gain in




0.07). The study had only













 receptor type II were elevated in both groups
before the study treatment began (Table 2). After
two weeks of treatment, both levels increased signif-
icantly more in the thalidomide group than in the




























0.005). There were no impor-
tant changes in CD4 or CD8 lymphocyte counts or
percentages from base line to week 4.
 





†Percentages shown are percentages of all lymphocytes.
‡Data are based on 26 patients in each group.































Age — yr 34.41.3 36.21.5
Weight — kg 61.92.1 66.23.0
Sex — no. (%)
Male 24 (86) 26 (90)
Female 4 (14) 3 (10)
Race or ethnic group — no. (%)
Non-Hispanic white 10 (36) 9 (31)
Non-Hispanic black 6 (21) 7 (24)
Hispanic 10 (36) 9 (31)
Asian or Pacific Islander 2 (7) 2 (7)























Area of ulcers — mm2 194.343.5 193.641.5
Mean quality-of-life score§ 3.00.2 3.10.2
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Virologic Data
The patients in the thalidomide group had a sig-
nificantly greater increase in HIV RNA from base
line to week 4 than the patients in the placebo group
(median increase in the thalidomide group, 0.42
log10 copies per milliliter; in the placebo group, 0.05;
P0.04). During the same interval, the increases in
HIV RNA were weakly associated with the increases
in plasma levels of TNF-a (r0.34, P0.05) and
soluble TNF-a receptor type II (r0.42, P0.01).
Safety
Six patients in the thalidomide group discontin-
ued the study medication because of toxic effects of
treatment. One of the 28 patients assigned to place-
bo requested an early discontinuation of treatment.
The estimated probability of remaining in the study
to day 28 without a dose reduction was 52 percent
in the thalidomide group and 89 percent in the pla-
cebo group.
Twelve patients assigned to thalidomide and 11
Figure 1. Major Aphthous Ulcer of Six Weeks’ Duration on the Palatopharyngeal Arch of a 30-Year-Old
Man with the Acquired Immunodeficiency Syndrome (AIDS).
AIDS was diagnosed on the basis of CD4 cell counts of less than 200 per cubic millimeter. The ulcer
healed completely, with little scarring, after four weeks of thalidomide therapy. In the photograph in
Panel A, obtained at the start of the study, the arrows indicate the location of the upper and lower
ulcer margins. In the photograph in Panel B, obtained after four weeks’ treatment with thalidomide,
the arrows indicate where the ulcer margins had been at the start of the study.
A
B
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patients assigned to placebo had new adverse events
of grade 3 or higher (as classified according to the
NIAID criteria) during the four weeks of random-
ized treatment. Grade 4 neutropenia occurred in
two thalidomide-treated patients who had severe
neutropenia before therapy. One patient in the tha-
lidomide group and two patients in the placebo
group had grade 3 neutropenia. Somnolence was re-
ported in seven patients in the thalidomide group
(24 percent) and two patients in the placebo group
(7 percent, P0.144). Seven patients in the thalid-
omide group (24 percent) had rashes, as compared
with one patient in the placebo group (4 percent,
P0.052). Other adverse events in the thalidomide
group, each observed in three patients or fewer, in-
cluded chest pain, respiratory difficulties, fever, con-
fusion, headaches, fatigue, dizziness, irregular heart-
beat, lethargy, nausea, syncope, elevated levels of
hepatic aminotransferases, and elevated levels of al-
kaline phosphatase. In the placebo group, the ad-
verse events included headaches, anemia, elevated
levels of g-glutamyltransferase, elevated levels of he-
patic aminotransferases, fever, diarrhea, fatigue, and
hallucinations. Seven patients in the thalidomide
group and five in the placebo group had new or
worsened peripheral sensory neuropathy.
During the first four weeks of study treatment,
there were no deaths or new episodes of opportun-
istic infections. No pregnancies occurred.
DISCUSSION
This double-blind, randomized, placebo-con-
trolled study shows that thalidomide is effective in
healing aphthous ulceration of the mouth and oro-
pharynx in HIV-infected patients. The ulcers healed
completely by week 4 in 55 percent of the patients
in the thalidomide group, as compared with 7 per-
cent of the patients in the placebo group. Almost all
the patients taking thalidomide (90 percent) had at
least partial healing. There was complete resolution
in some patients within as little as one week after the
start of therapy, but the median time to complete
healing among the patients who responded was 3.5
weeks. Quality-of-life measures clearly showed that
thalidomide reduced the pain from the aphthous le-
sions and improved the ability to eat.
There were no significant differences between the
groups in the incidence of serious adverse events,
Figure 2. Estimated Distribution of the Time Needed for Com-
plete Healing of Aphthous Ulcers in the 57 Patients, According
to Treatment Group.



































*P values are for the difference between groups.
†Positive values indicate that the level increased from base line to the week shown; negative values indicate that the level decreased. The levels during a
specified period around the date of the visit were averaged (in the case of base-line values, the measurements considered were made at or before the base-
line visit). Changes from base line are the differences between the average values. Mean (SD) normal values for TNF-a are 9.55.7 pg per milliliter; and
for soluble TNF-a receptor type II, 2.10.7 ng per milliliter. Data on 42 of the 57 patients were used in the analysis.
‡P0.05 by the two-sample Wilcoxon rank-sum test for the comparison of the difference in changes between groups.
§P0.05 by the Wilcoxon signed-rank test for the comparison of the base-line and post–base-line values within the group.




























Placebo 22 37.09 (22.32, 75.85)
0.870
20 0.31  (5.60, 3.55)
0.001‡
20 0.91  (9.49, 6.66)
0.090
Thalidomide 20 36.97 (25.97, 48.62) 16 12.16§ (5.63, 22.98) 14 4.04  (0.14, 8.83)
















0.05  (0.50, 0.28)
0.53§ (0.31, 1.06)
0.007‡
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but not all the patients could tolerate the initial
therapeutic regimen (200 mg per day) for the entire
four weeks of the randomized study. Approximately
half the patients either discontinued the study med-
ication permanently or had their doses reduced be-
fore the four-week course ended. Half of these treat-
ment changes were due to rash or excessive sedation.
Peripheral sensory neuropathy was not found with
greater frequency in the thalidomide group. How-
ever, such neuropathy is a known complication of
longer-term thalidomide treatment.29 Given the oth-
er neuropathic insults to which HIV-infected pa-
tients are exposed, patients receiving thalidomide
must be monitored carefully for this potential toxic
effect.
Thalidomide is notorious for its teratogenic ef-
fects.30-32 During the period of pregnancy when
there is known sensitivity to the effects of thalido-
mide (21 to 35 days after conception), even a single
dose of thalidomide is dangerous.31 If thalidomide is
given to women with childbearing potential, the
treatment should be accompanied by cautionary
measures, including careful informed-consent proce-
dures, a requirement that effective birth control be
used, testing for pregnancy every two weeks, warn-
ing labels on packages and vials, and preestablished
procedures for counseling and monitoring in the
event of pregnancy. We believe that this approach
should be used so that women with childbearing po-
tential can receive this treatment and other poten-
tially beneficial therapies of known or uncertain ter-
atogenic risk.
Recently, the immune-modulating and angiogen-
esis-inhibiting activities of thalidomide have been
recognized.33-35 The drug has shown evidence of ef-
fectiveness in treating graft-versus-host disease in
transplant recipients34 and in treating erythema no-
dosum leprosum.35 Most descriptions of the use of
thalidomide to treat aphthous ulcers in HIV-infect-
ed patients and others have been case reports and
retrospective series.3-14 However, one placebo-con-
trolled, double-blind, crossover trial with no wash-
out period reported success with 100 mg of thalid-
omide per day in presumably non–HIV-infected
subjects.15 End points related to both prophylaxis
and treatment were combined in that trial.
The cause of aphthous ulceration has not been es-
tablished. Viral, immunologic, hormonal, and stress-
related factors have all been suggested.36 Evidence of
HIV RNA or protein has been found in some mac-
rophages at the bases of esophageal ulcers in some
patients with the acquired immunodeficiency syn-
drome (AIDS).37 However, it is likely that the direct
cause of aphthous ulceration is immunologic36,37
and that the mechanism of action of thalidomide,
like that of corticosteroids, is based on its immune-
modulating properties.
Our study failed to elucidate the putative immuno-
logic mechanism, however. Although thalidomide was
reported to inhibit the production of TNF-a,16-20,38,39
our data did not show that TNF-a was inhibited, at
least not systemically. Plasma levels of both TNF-a
and soluble TNF-a receptor type II increased in the
thalidomide-treated patients as compared with those
receiving placebo. This suggests either that TNF-a
is not important in the pathogenesis of aphthous ul-
cers or that if it is, the effect may occur locally in the
tissues. It is more likely that other mechanisms are
involved.
Our data suggest that thalidomide enhances the
production of HIV. This contradicts in vitro find-
ings18 but is consistent with the results of our meas-
urements of TNF-a and lends support to the pro-
posed relation between the activation of TNF-a and
viral expression from HIV-infected cells.21 TNF-a
induces the expression of HIV from chronically in-
fected cell lines by stimulating nuclear factor-kB, a
cellular transcription factor used by HIV.21 Because
of the effect of thalidomide on the HIV load and on
the levels of soluble TNF-a receptor type II, two
measures associated with the clinical progression of
HIV disease,40-43 we urge caution in using thalido-
mide in HIV-infected persons after the two to four
weeks of short-term treatment.
Our data indicate that when large, nonhealing
aphthous ulcers of the gastrointestinal tract develop
in HIV-infected patients, the patients usually have
advanced immunosuppression. The median absolute
CD4 cell count in our patients was 25 cells per cubic
millimeter; 89 percent had CD4 counts of less than
200 cells per cubic millimeter. Thus, such ulceration
should probably be considered an AIDS-defining
event.
Few data are available on the incidence of severe
aphthous ulcers among HIV-infected patients. They
are certainly uncommon, but when they do occur
they are often devastating. Our study shows that tha-
lidomide is clearly effective in treating this condition.
Supported in part by the ACTG, NIAID; and in part by the General
Clinical Research Center Units funded by the National Center for Research
Resources.
We are indebted to Susan Stehn and Jana Parson for technical
support, to Evangeline Leash for editorial assistance, to Carmen Al-
icea for secretarial assistance, to the clinicians who referred patients
to the study, and to the patients who participated in it.
APPENDIX
In addition to the study authors, the ACTG protocol 251 team included:
D. Greenspan and F. Aweeka, University of California, San Francisco;
C. Trapnell and L. Purdue, Division of AIDS, NIAID; J. McFarland and
W. Levy, ACTG Operations Center, Social and Scientific Systems, Rock-
ville, Md.; G. Jones, Data Management Center, Frontier Science Technol-
ogy and Research Foundation, Amherst, N.Y.; D. Simpson, Mount Sinai
School of Medicine, New York; A. Bardequez, New Jersey Medical School,
Newark; R. Clark, Tulane University, New Orleans; N. Quesada, University
of California, Los Angeles; and P.J. Andrulis, Jr., and M.W. Drulak, Andru-
lis Pharmaceuticals, Beltsville, Md.
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Other investigators at participating sites were as follows: L. Bessen and
K. Luykx, Mount Sinai Medical Center, New York; S. Forstat, University of
California, San Francisco; M. Cruz-Ortiz, University of Puerto Rico, San
Juan; C. van der Horst, University of North Carolina, Chapel Hill; C.M.
Shikuma and D. Ogata-Arakaki, University of Hawaii, Manoa; J.S. Currier
and V.T. Clemente, University of Southern California, Los Angeles; J. Pul-
virenti and H. Kessler, Northwestern University, Chicago; T.M. Hooten
and A.C. Collier, University of Washington, Seattle; M. Guererro and
D. Duran, University of California, Los Angeles; S. Kirk and W.J. Fessel,
Stanford University, Palo Alto, Calif.; V. McAuliffe and J. Dowling, New
York University, New York; B.W. Zwickl and L.J. Wheat, Indiana Universi-
ty, Indianapolis; S.P. Raffanti and D.L. Greenspan, Meharry Medical Col-
lege, Nashville; H. Heller and L. Jackson-Pope, Harvard Medical School,
Boston; H. Teppler and C. Rossi, University of Pennsylvania, Philadelphia;
M.M. Lederman and M. Chance, Case Western Reserve University, Cleve-
land; S. Canmann and E. Connick, University of Colorado Health Sciences
Center, Denver; R. Hewitt and D. Blair, University of Rochester, Rochester,
N.Y.; and R. Soiero and D. Stein, Albert Einstein College of Medicine,
New York.
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